Cost-Effectiveness of Dapagliflozin Versus Dpp-4 Inhibitors as Monotherapy in the Treatment of Type 2 Diabetes Mellitus From A Uk Health Care Perspective
Value Health
.
2014 Nov;17(7):A347.
doi: 10.1016/j.jval.2014.08.709.
Epub 2014 Oct 26.
Authors
M Charokopou
1
,
H Vioix
2
,
B Verheggen
1
,
L A Eddowes
3
,
M Griffiths
3
,
Z Gabriel
2
,
K Tolley
4
,
D Franks
2
Affiliations
1
Pharmerit International, Rotterdam, The Netherlands.
2
AstraZeneca UK Ltd., Luton, UK.
3
Costello Medical Consulting Ltd., Cambridge, UK.
4
Tolley Health Economics Ltd., Buxton, Derbyshire, UK.
PMID:
27200659
DOI:
10.1016/j.jval.2014.08.709
No abstract available